Navigation Links
Pharmasset Reports Financial Results for Quarter Ended March 31, 2008
Date:5/15/2008

of 2008, assuming successful completion of the ongoing R7128 Phase 1

study, transfer of Pharmasset's IND to Roche, timely progress on agreed

development timelines, completion of all required Phase 2b study

preclinical and clinical preparation activities, manufacture of

clinical trial drug supply and agreement on the trial design from the

FDA and foreign regulatory authorities. An update will be provided as

soon as additional information is available.

-- Nominating a lead product candidate from a new series of potent anti

HCV molecules for IND or foreign regulatory equivalent filing and

first-in-human clinical trials.

About Pharmasset

Pharmasset is a clinical-stage pharmaceutical company committed to discovering, developing and commercializing novel drugs to treat viral infections. Pharmasset's primary focus is on the development of oral therapeutics for the treatment of hepatitis B virus (HBV), hepatitis C virus (HCV) and human immunodeficiency virus (HIV).

Pharmasset is currently developing three product candidates. Clevudine, for the treatment of chronic HBV infection, is enrolling Phase 3 clinical trials for registration in North, Central and South America and Europe. Clevudine is already approved for HBV in South Korea and marketed by Bukwang Pharmaceuticals in South Korea under the brand name Levovir. R7128, an oral treatment for chronic HCV infection, is in a 4-week Phase 1 clinical trial in combination with Pegasys(R) plus Copegus(R) through a strategic collaboration with Roche. Racivir, which is being developed for the treatment of HIV in combination with other approved HIV drugs, has completed a Phase 2 clinical trial.
Pegasys(R) and Copegus(R) are registered trademarks of Roche.

Contact

Alan Roemer, Vice President

Investor Relations & Corporate Communications

alan.roemer@pharma
'/>"/>

SOURCE Pharmasset, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine news :

1. Pharmasset to Present at the Rodman & Renshaw Healthcare Conference on Tuesday, May 20th
2. Pharmasset Appoints Patrick T. Higgins as Executive Vice President, Marketing & Sales
3. Pharmasset Presents R7128 14-Day Monotherapy Study Results for the Treatment of Chronic Hepatitis C
4. Pharmassets Underwriters Release Shares from Lock-Up
5. Nephros Reports 2008 First Quarter Financial Results
6. PreMD Reports First Quarter Results
7. Lifeway Foods Reports Record 1st Quarter 2008 Results
8. Corgenix Reports Third Quarter Fiscal 2008 Financial Results
9. Tiens Biotech Group (USA) Reports First Quarter Results
10. Cardiogenesis Reports First Quarter 2008 Results
11. STEN Corp. Reports 2008 Second-Quarter Revenue of $4.3 Million and Improved Results From Operations
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... 28, 2014 ABC television stars will ... MDA Show of Strength Telethon airing Sunday, Aug. 31, ... help raise funds and awareness to help save and ... muscle disease. , Viewers tuning into the 2014 telethon ... appeals and introductions from some of the network’s leading ...
(Date:8/28/2014)... 28, 2014 Biotronic, a Great Point ... neurophysiology monitoring ("IONM") company, today announced the promotion of ... Chief Executive Officer effective immediately. Mr. Gecsey joined Biotronic ... CFO in 2013 and has been an integral part ... efforts and achievements since joining the company in 2010 ...
(Date:8/28/2014)... 2014 Allegheny Health Network ... regional partnership designed to advance sports nutrition education, ... young athletes, scholastic athletes and their families across ... & Mind Initiative will offer a comprehensive and ... and mental dynamics involved in pursuing athletic excellence,” ...
(Date:8/28/2014)... 28, 2014 Valero Renewable Fuels Company, ... (NYSE: VLO), and the Ports of Indiana hosted Lt. ... today at a Port Appreciation and Welcome Celebration commemorating ... plant. , “The opening of Valero’s ethanol facility at ... economic development win for the State of Indiana,” Ellspermann ...
(Date:8/28/2014)... (PRWEB) August 28, 2014 Gurnick Academy ... MRI Technology program is re-accredited for the 5 years ... Resonance Imaging Technologists (ARMRIT). , “We are very ... constantly improving our program to make sure we provide ... lot of interest in MRI field nowadays and I ...
Breaking Medicine News(10 mins):Health News:ABC Stars Unite to Fight Back Against Muscle Disease During MDA Show of Strength Telethon 2Health News:ABC Stars Unite to Fight Back Against Muscle Disease During MDA Show of Strength Telethon 3Health News:ABC Stars Unite to Fight Back Against Muscle Disease During MDA Show of Strength Telethon 4Health News:Biotronic NeuroNetwork Announces the Promotion of Bill Gecsey to CEO 2Health News:Allegheny Health Network and Come Ready Nutrition Announce Regional Partnership 2Health News:Allegheny Health Network and Come Ready Nutrition Announce Regional Partnership 3Health News:Allegheny Health Network and Come Ready Nutrition Announce Regional Partnership 4Health News:Valero, Ports of Indiana Celebrate Restart of Ethanol Plant 2Health News:Valero, Ports of Indiana Celebrate Restart of Ethanol Plant 3Health News:Gurnick Academy’s MRI Program Is Re-Accredited by ARMRIT for the 5 Years 2
... a blood vessel medication, improved distances 50% ... prescription drug naftidrofuryl eases leg cramps caused by ... farther, according to Belgian researchers. , They reviewed ... condition called intermittent claudication. Patients who took the ...
... Brain function and health will be the focus of the ... in San Francisco. Part of a highly recognized series, ... with the booming aging industry; factors that predict future cognitive ... participate in them. , WHO: , The program is sponsored ...
... On Sunday, June 29,2008, West Coast Bank will sponsor ... Run, Portland,s most unique 8k personal,challenge run., Race ... the,Burnside Bridge by 9:00 a.m. when the bridge rises. ... the Oregon Zoo and winds through the,paved roads of ...
... are estimated to be affected by the devastation caused ... by researchers from the Johns Hopkins Bloomberg School of ... Systems (GIS), the researchers calculated the likely distribution of ... developed maps of the regions at greatest risk from ...
... and Vancouver Coastal Health Research Institute have discovered how ... body and are working toward a treatment to block ... discovery, published today in the journal Cell Host and ... and its newly discovered counterpart protein in the human ...
... broader public action to curb effects , , WEDNESDAY, May 14 ... particulate matter air pollution can increase blood pressure and harm ... , The findings may explain why air pollution can trigger ... failure and stroke, the researchers said. , Particulate matter (PM) ...
Cached Medicine News:Health News:Common Drug Eases Leg Pain From Walking 2Health News:Estimated 3.2 million Burmese potentially affected by cyclone 2Health News:Vancouver researchers discover missing link between TB bacteria and humans 2Health News:Pollution Particles Impair Blood Vessel Function 2
(Date:8/28/2014)... Aug. 28, 2014 Telik, Inc. (OTCQB: TELK), ... merged with MabVax Therapeutics, Inc. on July 8, ... related to the development of its lead antibody ... using the Company,s internally developed antibody discovery platform. ... multiple antibody based therapeutic and diagnostic products based ...
(Date:8/28/2014)... N.H. , Aug. 28, 2014  Critical ... Hampshire , today announces the expansion of ... Critical Process Filtration now offers customers and ... in fluids to filter failure analyses (even for ... addition to their hallmark services of system benchmarking ...
(Date:8/28/2014)... , Aug. 28, 2014  A decline in ... generics are adding pressure to pharmaceutical, biotechnology and ... resources continue to shrink and approval processes and ... led companies to look for additional support and ... for keeping approved products on the market.  ...
Breaking Medicine Technology:Telik Reports Progress Toward Multiple Early Stage Milestones in the Development of a Novel Antibody-based Therapeutic Agent for Gastrointestinal Cancers 2Telik Reports Progress Toward Multiple Early Stage Milestones in the Development of a Novel Antibody-based Therapeutic Agent for Gastrointestinal Cancers 3Telik Reports Progress Toward Multiple Early Stage Milestones in the Development of a Novel Antibody-based Therapeutic Agent for Gastrointestinal Cancers 4Critical Process Filtration, Inc. Announces Expanded Technical Services and Validation Support 24 Key Factors to Consider When Choosing an Effective Regulatory Outsourcing Partner 24 Key Factors to Consider When Choosing an Effective Regulatory Outsourcing Partner 34 Key Factors to Consider When Choosing an Effective Regulatory Outsourcing Partner 4
... , SARASOTA, Fla. , Jan. 15 ... its Senior Subordinated Convertible Notes due 2034 (CUSIP No. 776696AA4) (the "Notes") ... to July 15, 2010 at an annual rate of ... trading days ended July 13, 2010 . Contingent cash interest, which ...
... , SCOTTSDALE, Ariz. , Jan. 15 ... pharmaceutical competitive intelligence and market research, has published a ... therapies to treat hematologic malignancies.  These reports are based ... America immediately following the American Society of Hematology ...
Cached Medicine Technology:New MedPredict Report Highlights Recent Advances in Management of Malignant Hematology 2
96 channel Parallel dispenser using Positive Air Displacement Technology...
The WellPro 384 is designed for use with 384 well microplates. It utilizes a 24 channel liquid head and can perform serial dilutions in a 16 or 24 across format, and plate to plate transfers and plat...
The WP1000S is a shortened base version of the WellPro that is shortened 5 inches to facilitate fitting into smaller biohazard hoods....
... The Labcyte Echo 550 compound ... droplets down to 5 nL using ... on focused acoustic energy. Monitoring of ... fluids enables the Echo 550 to ...
Medicine Products: